Clinical trials: Non-squamous, Non-Small Cell Lung Cancer
Non-small-cell Lung Cancer
Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
- Trial name
- NCT02577341
- Testing
- Nimotuzumab, docetaxel and cisplatin, daily RT to the chest
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sun Yat-sen University
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Non-small Cell Lung Cancer
REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer
The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of…
- Trial name
- NCT03515629
- Testing
- REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 5 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced NSCLC With EGFR Mutation
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus gefitinib versus gefitinib monotherapy
- Trial name
- NCT03457337
- Testing
- S-1 plus Gefitinib, Gefitinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer
Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases
The patients carrying a complicated primary lung cancer brain metastases die in less than 3 months of delay disease in the absence of treatment.
- Conditions
- Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer, Adenocarcinoma of Lung Metastatic to Brain, Cerebral Metastases
- Trial name
- METAL2 (NCT02162537)
- Testing
- Cisplatin, Pemetrexed, Bevacizumab
- Where
- 41 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Carcinoma, Non-Small-Cell Lung
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer
- Trial name
- AVANA (NCT02810457)
- Testing
- FKB238 (bevacizumab), Avastin (bevacizumab), Paclitaxel
- Where
- 147 sites in United States, Belarus and 22 more
- Volunteers
- 731 people
- Sponsor
- Centus Biotherapeutics Limited
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Advanced Solid Tumor
Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
This study is a Phase I/IIa, multi-center, open-label study of BR790 in combination with Tislelizumab with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.
- Trial name
- NCT05505877
- Testing
- BR790+Tislelizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Gopherwood Biotech Co., Ltd.
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
This phase I trial studies the side effects and the best dose of Hsp90 inhibitor AUY922 when given together with pemetrexed disodium in treating patients with previously treated stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01784640
- Testing
- Hsp90 inhibitor AUY922, pemetrexed disodium, pharmacological study
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lung Cancer
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276588
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Squamous Non-Small Cell Lung Carcinoma
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1…
- Trial name
- NCT05127590
- Testing
- RBN-2397
- Where
- 19 sites in United States, Israel and 2 more
- Volunteers
- 50 people
- Sponsor
- Ribon Therapeutics, Inc.
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
- Conditions
- Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
- Trial name
- NCT07613723
- Testing
- ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Zelluna Immunotherapy AS
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Carcinoma, Non-Small-Cell Lung
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
This is a phase II, single institution trial for patients with clinical Stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable lung tumors.
- Trial name
- NCT00130780
- Testing
- Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Non-small Cell Lung Cancer
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy…
- Trial name
- NCT03390686
- Testing
- Bevacizumab, HD204, Carboplatin
- Where
- 18 sites in Belarus, Bulgaria and 15 more
- Volunteers
- 650 people
- Sponsor
- Prestige Biopharma Limited
Non-squamous Cell Non-Small Cell Lung Cancer
Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC
In recent years, with the progress in the treatment field, NSCLC has become the most successful cancer species in precision medicine.
- Trial name
- ALTER-L025 (NCT03778138)
- Testing
- Anlotinib plus Pemetrexed
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Henan Provincial People's Hospital
Non-squamous Non-small-cell Lung Cancer
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.
- Trial name
- NCT04619433
- Testing
- Camrelizumab;Pemetrexed and Carboplatin; Famitinib;
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.